MSDC 0602

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

MSDC-0602 是一种可能用于治疗糖尿病的胰岛素增敏剂。

MSDC-0602 is an insulin sensitizer potentially for the treatment of diabetes (metabolic modulator).

——

Animal Model:HTF-C diet feeding C57BL6/J mice Dosage:331 ppm MSDC-0602 potassium salt (2-5 μM MSDC-0602 in blood)Administration:oral administration for 12 weeks (after 4 weeks of HTF-C diet) or 3 weeks (16 weeks after HTF-C diet)Result:Induced weight loss, decreased concentrations of plasma ALT and AST and stellate cell activation.Animal Model:HTF-C diet feeding LS-Mpc2-/-C57BL6/J mice Dosage:331 ppm MSDC-0602 potassium salt (2-5 μM MSDC-0602 in blood) Administration:oral administration for 12 weeks (after 4 weeks of HTF-C diet)Result:Induced weight loss, suppressed stellate cell activation.

MSDC-0602 | MSDC0602

Others

Other Targets

mTOR

——

——

1133819-87-0

371.4

C19H17NO5S

>98% (HPLC)

DMSO : 125 mg/mL 336.56 mM; H2O : < 0.1 mg/mL

COc1cccc(c1)C(=O)COc3ccc(CC2SC(=O)NC2=O)cc3

5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione

(-20℃)

With Ice Pack

≥ 2 years